Should I buy or sell Prothena stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRTA shares. View PRTA analyst ratings or view top-rated stocks .

What is Prothena's stock price target for 2024?

7 equities research analysts have issued 1 year price objectives for Prothena's shares. Their PRTA share price targets range from $72.00 to $129.00. On average, they predict the company's share price to reach $91.00 in the next twelve months. This suggests a possible upside of 175.8% from the stock's current price. View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts .

How have PRTA shares performed in 2023?

Prothena's stock was trading at $60.25 on January 1st, 2023. Since then, PRTA stock has decreased by 45.2% and is now trading at $33.00. View the best growth stocks for 2023 here .

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our PRTA earnings forecast .

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.64. The biotechnology company earned $84.87 million during the quarter, compared to analysts' expectations of $51.85 million. Prothena had a negative net margin of 51.92% and a negative trailing twelve-month return on equity of 12.06%.

What ETFs hold Prothena's stock?

ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , ALPS Medical Breakthroughs ETF (SBIO) , Alpha Architect U.S. Quantitative Momentum ETF (QMOM) , BNY Mellon Innovators ETF (BKIV) , SPDR S&P Biotech ETF (XBI) , Principal Healthcare Innovators ETF (BTEC) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Nasdaq Pharmaceuticals ETF (FTXH) .

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA) , Actinium Pharmaceuticals (ATNM) , ArcelorMittal (MT) , Merck & Co., Inc. (MRK) , Energous (WATT) , BioLineRx (BLRX) , Gilead Sciences (GILD) , Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD) .

Who are Prothena's major shareholders?

Prothena's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.96%), Rock Springs Capital Management LP (1.14%), Bank of New York Mellon Corp (0.93%), Northern Trust Corp (0.76%), JPMorgan Chase & Co. (0.75%) and Avidity Partners Management LP (0.71%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp , Christopher S Henney, Christopher S Henney , Dennis J Selkoe, Dennis J Selkoe , Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker , Lars Ekman, Michael J Malecek, Michael J Malecek , Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago . View institutional ownership trends .

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Prothena Stock Price, News & Analysis (NASDAQ:PRTA)

$33.00

+0.52 (+1.60%)

(As of 11/29/2023 ET)

Compare

Today's Range: $32.65
▼
$33.89
50-Day Range: $32.31
▼
$52.32
52-Week Range: $28.51
▼
$79.65

Volume: 461,543 shs
Average Volume: 506,983 shs
Market Capitalization: $1.77 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $91.00

Prothena MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 175.8% Upside
$91.00 Price Target
Short Interest: Bearish
11.53% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: Selling Shares
$2.01 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.76) to ($4.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

443rd out of 949 stocks

Pharmaceutical Preparations Industry

198th out of 432 stocks

3.5

Analyst's Opinion

Consensus Rating
Prothena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $91.00, Prothena has a forecasted upside of 175.8% from its current price of $33.00.
Amount of Analyst Coverage
Prothena has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.53% of the outstanding shares of Prothena have been sold short.
Short Interest Ratio / Days to Cover
Prothena has a short interest ratio ("days to cover") of 9.6.
Change versus previous month
Short interest in Prothena has recently decreased by 4.77%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Prothena does not currently pay a dividend.
Dividend Growth
Prothena does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRTA.

2.7

News and Social Media Coverage

News Sentiment
Prothena has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Prothena this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for PRTA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
2 people have added Prothena to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prothena insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,005,770.00 in company stock.
Percentage Held by Insiders
28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Prothena are expected to decrease in the coming year, from ($2.76) to ($4.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prothena is -23.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prothena is -23.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prothena has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PRTA Stock News Headlines

November 28, 2023 | americanbankingnews.com

Prothena Co. plc (NASDAQ:PRTA) Receives Consensus Rating of "Buy" from Analysts

November 18, 2023 | ca.finance.yahoo.com

PRTA Dec 2023 105.000 call

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 6, 2023 | markets.businessinsider.com

Cantor Fitzgerald Keeps Their Buy Rating on Prothena (PRTA)

November 3, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Prothena (PRTA)

November 3, 2023 | finance.yahoo.com

Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue Hike

November 2, 2023 | markets.businessinsider.com

Rudy Li’s Confidence in Prothena’s Potential: Overcoming Challenges and Delivering Strong Results

November 2, 2023 | msn.com

Prothena (PRTA) Beats Q3 Earnings and Revenue Estimates

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 2, 2023 | finanznachrichten.de

Prothena Corporation plc: Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

November 2, 2023 | finance.yahoo.com

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

November 1, 2023 | benzinga.com

Earnings Preview For Prothena Corp

October 27, 2023 | markets.businessinsider.com

Prothena’s Stock Buy Rating: Potential Impact of Eisai/Biogen’s Leqembi Sub-Q Data and Implications for PRX012

October 27, 2023 | markets.businessinsider.com

Prothena’s Stock Retains Buy Rating Amidst Adjusted Penetration Projections and Awaited Clinical Data: Tazeen Ahmad’s Analysis

October 26, 2023 | finanznachrichten.de

Prothena Corporation plc: Prothena to Report Third Quarter 2023 Financial Results on November 2

October 26, 2023 | msn.com

Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy

October 26, 2023 | finance.yahoo.com

Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

October 18, 2023 | finance.yahoo.com

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

October 17, 2023 | finance.yahoo.com

Prothena (PRTA) Soars 18.7%: Is Further Upside Left in the Stock?

October 16, 2023 | ca.investing.com

Prothena Corp. exploring a potential sale - Bloomberg

October 16, 2023 | benzinga.com

Why Is Alzheimer's Player Prothena Stock Trading Higher Today?

October 16, 2023 | reuters.com

Prothena prepares for potential sale - Bloomberg News

October 16, 2023 | proactiveinvestors.com

Prothena shares buoyed by sale rumors

October 13, 2023 | finance.yahoo.com

We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth

October 12, 2023 | finance.yahoo.com

Insider Sell: Brandon Smith Sells 4,000 Shares of Prothena Corp PLC

October 6, 2023 | markets.businessinsider.com

Piper Sandler Remains a Buy on Prothena (PRTA)

October 5, 2023 | finance.yahoo.com

Insider Sell: Chief Regulatory Officer Carol Karp Sells 5,000 Shares of Prothena Corp PLC

See More Headlines

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRTA
CUSIP: N/A
CIK: 1559053
Web: www.prothena.com
Phone: (531) 236-2500
Fax: 353-1902-3510
Employees: 127
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $91.00
High Stock Price Target: $129.00
Low Stock Price Target: $72.00
Potential Upside/Downside: +174.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-116,950,000.00
Net Margins: -51.92%
Pretax Margin: -61.37%
Return on Equity: -12.06%
Return on Assets: -9.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.94
Quick Ratio: 12.94

Sales & Book Value

Annual Sales: $53.90 million
Price / Sales: 32.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.50 per share
Price / Book: 2.88

Miscellaneous

Outstanding Shares: 53,670,000
Free Float: 38,531,000
Market Cap: $1.78 billion
Optionable: Optionable
Beta: 0.45

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Gene G. Kinney Ph.D. (Age 54)
President, CEO & Director
Comp: $1.03M
Mr. Tran B. Nguyen M.B.A. (Age 49)
CFO & Chief Strategy Officer
Comp: $762.86k
Mr. Brandon S. Smith (Age 48)
Chief Operating Officer
Comp: $756.41k
Ms. Carol D. Karp (Age 70)
Chief Regulatory Officer
Comp: $697.51k
Dr. Hideki Garren M.D. (Age 58)
Ph.D., Chief Medical Officer
Comp: $809.59k
Ms. Karin L. Walker CPA (Age 60)
Chief Accounting Officer & Controller
Dr. Wagner M. Zago (Age 50)
Chief Scientific Officer
Comp: $478.79k
Ms. Jennifer Zibuda
Director of Investor Relations & Communication
Mr. Michael J. Malecek (Age 57)
Chief Legal Officer & Company Secretary
Comp: $588.25k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRTA shares.
View PRTA analyst ratings or view top-rated stocks.
What is Prothena's stock price target for 2024?: 7 equities research analysts have issued 1 year price objectives for Prothena's shares. Their PRTA share price targets range from $72.00 to $129.00. On average, they predict the company's share price to reach $91.00 in the next twelve months. This suggests a possible upside of 175.8% from the stock's current price.
View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts.
How have PRTA shares performed in 2023?: Prothena's stock was trading at $60.25 on January 1st, 2023. Since then, PRTA stock has decreased by 45.2% and is now trading at $33.00.
View the best growth stocks for 2023 here.
When is Prothena's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our PRTA earnings forecast.
How were Prothena's earnings last quarter?: Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.64. The biotechnology company earned $84.87 million during the quarter, compared to analysts' expectations of $51.85 million. Prothena had a negative net margin of 51.92% and a negative trailing twelve-month return on equity of 12.06%.

What ETFs hold Prothena's stock?: ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).
What other stocks do shareholders of Prothena own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).
Who are Prothena's major shareholders?: Prothena's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.96%), Rock Springs Capital Management LP (1.14%), Bank of New York Mellon Corp (0.93%), Northern Trust Corp (0.76%), JPMorgan Chase & Co. (0.75%) and Avidity Partners Management LP (0.71%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends.
How do I buy shares of Prothena?: Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial